#### **CURRICULUM VITAE**

### **PERSONAL HISTORY**

Name: Hannele Yki-Järvinen Nationality: Finnish

### **EDUCATION AND ACADEMIC DEGREES**

Specialty: Internal Medicine, University of Helsinki 1993 Subspecialty: Endocrinology, University of Helsinki 1994

Fellow of the Royal College of Physicians (F.R.C.P.), London 1999

### PRESENT POSITION

*Professor of Medicine* (with tenure), University of Helsinki, Department of Medicine 1.12.1997→

# PREVIOUS PROFESSIONAL APPOINTMENTS (shortened)

Professor, Academy of Finland, University of Helsinki, Department of Endocrinology and Diabetes 1.8.1995-31.7.2000

Nordic Professor i Medicin, Karolinska Institutet, Department of Medicine, 1.1.2002-31.12.2004 Professor, Academy of Finland, University of Helsinki, Department of Endocrinology and Diabetes 1.8.2000-31.7.2005

### INTERNATIONAL AWARDS

- 1) 1993 G. B. Morgagni Young Investigator Award, Padova, Italy
- 2) 1993 The 28th *Minkowski* Award, European Association for the Study of Diabetes, Istanbul, Turkey
  - The highest ranking scientific award in the field of diabetes in Europe
  - Given for the first time to a Finn, a female investigator and to a clinical investigator
- 3) 1995 Anders Jahre Pris, University of Oslo, Oslo, Norway
  - The highest ranking award in medical sciences in Scandinavia
  - Given for excellence in research in any area of medical research (basic and clinical sciences)
- 4) 1999 Novartis Award in Diabetes, American Diabetes Association, San Diego, USA
- 5) 2008 The 16<sup>th</sup> Servier Lecture of the Diabetes Center, Manila, Philippines
- 6) 2008 Dr. Augusto D. Litonjua Endowed Lectureship, Manila, Philippines
- 7) 2011 Harold Rifkin visiting Professorship. Albert Einstein College of Medicine, New York USA

### SUPERVISION OF DOCTORAL THESES

Supervised a total of 29 doctoral these,, in 2018 the one by Panu Luukkonen was selected as the 'Thesis of the Year in Finland' by the Finnish Medical Association. The finalists were chosen by individual universities in Finland.

### **RESEARCH INTEREST**

Pathogenesis of insulin resistance and non-alcoholic fatty liver disease in humans

#### **INVITED LECTURES**

Over 400 invited lectures in over 40 countries in Europe, US, Asia, Australia, Africa and Sout-America

### **BIBLIOMETRICS**

Ranked as # 579 amongst 100 000 investigators in the world (1<sup>st</sup> of the University of Helsinki, 2<sup>nd</sup> in Finland)

 based on H-index, citations, publication efficacy, impact of research as described by the recent study from the University of Stanford (Ioannidis JPA ym. PLoS Biol 2019;17(8):e3000384. doi: 10.1371/journal.pbio.3000384.)

Ranked #179 of all female scientists in the world (H-Index 135, citations 63 366) (<a href="https://research.com/scientists-rankings/best-female-scientists">https://research.com/scientists-rankings/best-female-scientists</a>)

## **ACTIVITIES IN SCIENTIFIC ORGANIZATIONS**

# Treatment guidelines

- EASD/EASL/EASO member of the guideline writing group: EASL-EASD-EASO Clinical PracticeGuidelines for the management of *Non-alcoholic Fatty Liver Disease* (simultaneously published 2016 in <u>J Hepatol, Diabetologia and Obesity Facts</u>)
- Chairperson, development of National Guidelines for Non-alcoholic Fatty Liver Disease 2020
  → 2021
- EASD/EASL/EASO member of the guideline writing group 2022-

## Meeting organizer 2020-, international

- The EASL NAFLD 2020 Summit, Sep 17-19, 2020 Dublin, Ireland (1 of 3 organizers)
- Keystone Symposium, *Fatty Liver Disease and Multi-System Complications*, March 21-25, 2021, Fairmont Hotel Vancouver, British Columbia, Canada (1 of 3 organizers)
- NASH TAG meeting, Utah, USA, Scientific Advisory Committee, 2017-

# A FEW PUBLICATIONS RELEVANT FOR NAFLD

Luukkonen PK, Qadri S, Ahlholm N, Porthan K, Männistö V, Sammalkorpi H, Penttilä AK, Hakkarainen A, Lehtimäki TE, Gaggini M, Gastaldelli A, Ala-Korpela M, Orho-Melander M, Arola J, Juuti A, Pihlajamäki J, Hodson L, **Yki-Järvinen H**. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. <u>J Hepatol</u> 76:526-535, 2022 [30.083 for 2021]

Yki-Järvinen H, Luukkonen PK, Hodson L, Moore B: Dietary carbohydrates and fats in NAFLD. *Nature Reviews Gastroenterology & Hepatology*, 18: 770-786, 2021 [Impact factor 73.082 for 2020]

Luukkonen PK, Dufour S, Lyu K, Zhang XM, Hakkarainen A, Lehtimäki TE, Cline GW, Petersen KF, Shulman GI, Yki-Järvinen H. Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease. *Proc Natl Acad Sci U S A* 117: 7347-7354, 2020

Luukkonen PK, Zhou Y, Sädevirta S, Leivonen M, Arola J, Orešič M, Hyötyläinen T, Yki-Järvinen H. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. *J Hepatol* 64:1167-75, 2016

Yki-Järvinen H: Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. *Lancet Diabetes Endocrinol* 2: 901-910. 2014

Westerbacka J, Kotronen A, Fielding BA, Wahren J, Hodson L, Perttilä J, Seppänen-Laakso T, Suortti T, Arola J, Hultcrantz R, Castillo S, Olkkonen VM, Frayn KN, Orešic M, Yki-Järvinen H. Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease. *Gastroenterology* 139: 1961-1971, 2010 [12.899]

Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, Lundbom N, Rissanen A, Ridderstråle M, Groop L, Orho-Melander, M, Yki-Järvinen H Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors. *Gastroenterology* 137: 865-872, 2009

Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Järvinen H. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. *Gastroenterology* 135: 122-30, 2008